

YESCARTA and TECARTUS REMS Program  
REMS Program Training Program – Table  
Month Year

|  |  | <b>Slide Number (new)</b> | <b>Proposed Content (new)</b>  |
|--|--|---------------------------|--|
|  |  | 1                         | <b>YESCARTA® and TECARTUS™ Risk Evaluation and Mitigation Strategy (REMS) Program Training</b>   |
|  |  | 2                         | The educational module contains information on adverse reactions associated with YESCARTA and TECARTUS, including cytokine release syndrome and neurologic toxicities. These are not all of the adverse reactions associated with YESCARTA and TECARTUS.   |
|  |  | 3                         | <p><b>Indication - YESCARTA®</b><br/>YESCARTA® is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.</p> <p><u>Limitation of Use:</u> YESCARTA® is not indicated for the treatment of patients with primary central nervous system lymphoma.</p> <p>Please see full Prescribing Information, including <b>BOXED WARNING</b> and Medication Guide.</p> |
|  |  | 4                         | <p><b>Indication – TECARTUS™</b><br/>TECARTUS™ is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL)</p>  |

|  |  | <b>Slide Number (new)</b> | <b>Proposed Content (new)</b>  |
|--|--|---------------------------|--|
|  |  |                           | Please see full Prescribing Information, including <b>BOXED WARNING</b> and Medication Guide.  |
|  |  | 5                         | <b>YESCARTA and TECARTUS REMS Program Overview</b>   |
|  |  | 6                         | <p><b>What is the YESCARTA and TECARTUS REMS (Risk Evaluation and Mitigation Strategy) Program?</b></p> <p>A REMS Program is a strategy to manage known or potential risks associated with a drug and is required by the United States (US) Food and Drug Administration (FDA) to ensure that the benefits of the drug outweigh its risks. YESCARTA and TECARTUS are available only under a program called the YESCARTA and TECARTUS REMS Program because of the serious risks of cytokine release syndrome (CRS) and neurologic toxicities.</p> <p>The goals of the YESCARTA and TECARTUS REMS Program are to mitigate the risks of CRS and neurologic toxicities by:</p> <ul style="list-style-type: none"> <li>• Ensuring that hospitals and their associated clinics that dispense YESCARTA and/or TECARTUS are specially certified and have on-site, immediate access to a minimum of 2 doses of tocilizumab</li> <li>• Ensuring that those relevant individuals who prescribe, dispense, or administer YESCARTA and/or TECARTUS are aware of how to manage the risks of CRS and neurologic toxicities</li> </ul> |
|  |  | 7                         | <p><b>Hospital Certification</b></p> <p>To become certified to dispense YESCARTA and/or TECARTUS, hospitals and their associated clinics must:</p> <ol style="list-style-type: none"> <li>1. Designate an authorized representative to complete the training program by completing and submitting the YESCARTA and TECARTUS REMS Program Hospital Enrollment Form on behalf of the hospital and its associated clinics</li> <li>2. Ensure that the authorized representative oversees implementation and compliance with the YESCARTA and TECARTUS REMS Program requirements</li> </ol>  |

|  |  | <b>Slide Number (new)</b> | <b>Proposed Content (new)</b>   |
|--|--|---------------------------|---|
|  |  |                           | <p>3. Dispense YESCARTA and/or TECARTUS only after verifying that a minimum of 2 doses of tocilizumab are available on-site for each patient and ready for administration within 2 hours</p> <p>4. Recertify in the YESCARTA and TECARTUS REMS Program if a new authorized representative is designated</p>   |
|  |  | 8                         | <p><b>Hospital Certification (continued)</b></p> <p>5. Maintain documentation that all processes and procedures are in place and are being followed for the YESCARTA and TECARTUS REMS Program; provide this documentation upon request to Kite, or a third party acting on behalf of Kite or FDA</p> <p>6. Comply with audits by Kite, or a third party acting on behalf of Kite or FDA, to ensure that all training, processes, and procedures are in place and are being followed for the YESCARTA and TECARTUS REMS Program</p> <p>7. Report any serious adverse events* suggestive of CRS or neurologic toxicities</p> <p>* Serious adverse events are defined as any adverse experience occurring at any dose that results in any of the following outcomes: death, a life-threatening adverse experience, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect</p> |
|  |  | 9                         | <p><b>Who Can Be an Authorized Representative?</b></p> <p>An authorized representative at the hospital and its associated clinics can be a:</p> <ul style="list-style-type: none"> <li>• Physician</li> <li>• Nurse</li> <li>• Any responsible individual assigned by the hospital and its associated clinics</li> </ul> <p>One representative (the “authorized representative”) must enroll for each hospital and its associated clinics and attest to the enrollment requirements as stated on the YESCARTA and TECARTUS REMS Program Hospital Enrollment Form.</p>   |

|  |  | <b>Slide Number (new)</b> | <b>Proposed Content (new)</b>   |
|--|--|---------------------------|---|
|  |  | 10                        | <p><b>YESCARTA and TECARTUS REMS Authorized Representative Attestations</b></p> <ul style="list-style-type: none"> <li>• Complete the YESCARTA and TECARTUS REMS Program Training and successfully complete the YESCARTA and TECARTUS REMS Program Knowledge Assessment</li> <li>• Submit the completed YESCARTA and TECARTUS REMS Program Hospital Enrollment Form to Kite via fax at 1-310-496-0397 or email to <a href="mailto:YTREMS@kitepharma.com">YTREMS@kitepharma.com</a></li> <li>• Submit the YESCARTA and TECARTUS REMS Program Knowledge Assessment to Kite via fax at 1-310-496-0397 or email to <a href="mailto:YTREMS@kitepharma.com">YTREMS@kitepharma.com</a></li> <li>• Oversee implementation and compliance with the YESCARTA and TECARTUS REMS Program</li> </ul>   |
|  |  | 11                        | <p><b>YESCARTA and TECARTUS REMS Authorized Representative Attestations (continued)</b></p> <ul style="list-style-type: none"> <li>• Ensure that the hospital and its associated clinics will establish processes and procedures that are subject to monitoring by Kite or a third party acting on behalf of Kite to help ensure compliance with the requirements of the YESCARTA and TECARTUS REMS Program, including the following, before administering YESCARTA and/or TECARTUS:             <ul style="list-style-type: none"> <li>- Ensure that all relevant staff involved in the prescribing, dispensing, or administering of YESCARTA and/or TECARTUS are trained on the REMS Program requirements as described in the training materials, successfully complete the YESCARTA and TECARTUS REMS Program Knowledge Assessment, and maintain training records for all staff</li> </ul> </li> </ul> |

|  |  | <b>Slide Number (new)</b> | <b>Proposed Content (new)</b>   |
|--|--|---------------------------|---|
|  |  |                           | <ul style="list-style-type: none"> <li>▪ The Authorized Representative will determine relevant staff who require training</li> <li>- Put processes and procedures in place to ensure that staff involved in the prescribing, dispensing, or administering of YESCARTA and/or TECARTUS are retrained if YESCARTA or TECARTUS has not been dispensed at least once annually from the date of certification in the YESCARTA and TECARTUS REMS Program</li> <li>- Prior to dispensing YESCARTA and/or TECARTUS, put processes and procedures in place to verify a minimum of 2 doses of tocilizumab are available on-site for each patient and are ready for immediate administration (within 2 hours)</li> <li>- Prior to patient discharge, provide patients/caregivers with the Patient Wallet Card</li> </ul> |
|  |  | 12                        | <b>Serious Risks of YESCARTA and TECARTUS</b>   |
|  |  | 13                        | <p><b>Serious Risks Associated With YESCARTA</b><br/> <b>BOXED WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITIES</b></p> <ul style="list-style-type: none"> <li>• Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving YESCARTA. Do not administer YESCARTA to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids</li> <li>• Neurologic toxicities, including fatal or life-threatening reactions, occurred in patients receiving YESCARTA, including concurrently with CRS or after CRS resolution. Monitor for neurologic toxicities after treatment with</li> </ul>   |

|  |  | <b>Slide Number (new)</b> | <b>Proposed Content (new)</b>   |
|--|--|---------------------------|---|
|  |  |                           | YESCARTA. Provide supportive care and/or corticosteroids as needed  |
|  |  | 14                        | <p><b>Serious Risks Associated With TECARTUS</b><br/> <b>BOXED WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITIES</b></p> <ul style="list-style-type: none"> <li>• Cytokine Release Syndrome (CRS), including life-threatening reactions, occurred in patients receiving TECARTUS. Do not administer TECARTUS to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids</li> <li>• Neurologic toxicities, including life-threatening reactions, occurred in patients receiving TECARTUS, including concurrently with CRS or after CRS resolution. Monitor for neurologic toxicities after treatment with TECARTUS. Provide supportive care and/or corticosteroids, as needed</li> </ul> |
|  |  | 15                        | <b>Management of CRS</b>  |
|  |  | 16                        | <p><b>Cytokine Release Syndrome - YESCARTA</b></p> <ul style="list-style-type: none"> <li>• CRS, including fatal or life-threatening reactions, occurred following treatment with YESCARTA</li> <li>• In a Kite clinical trial, CRS occurred in 94% (101/108) of patients receiving YESCARTA, including Grade 3 or higher CRS in 13% (14/108) of patients</li> <li>• The median time to onset was 2 days (range, 1-12 days)</li> <li>• The median duration of CRS was 7 days (range, 2-58 days)</li> <li>• 45% (49/108) of patients received tocilizumab after infusion of YESCARTA</li> <li>• Among patients who died after receiving YESCARTA®, 4 had ongoing CRS events at the time of death</li> </ul>  |

|  |  | <b>Slide Number (new)</b> | <b>Proposed Content (new)</b>   |
|--|--|---------------------------|---|
|  |  | 17                        | <p><b>Cytokine Release Syndrome – TECARTUS</b></p> <ul style="list-style-type: none"> <li>• CRS, including life-threatening reactions, occurred following treatment with TECARTUS</li> <li>• In a Kite clinical trial, CRS occurred in 91% (75/82) of patients receiving TECARTUS, including Grade 3 or higher CRS in 18% of patients</li> <li>• The median time to onset was 3 days (range, 1-13 days)</li> <li>• The median duration of CRS was 10 days (range, 1-50 days)</li> </ul>               |
|  |  | 18                        | <p><b>Patient Assessment of CRS Associated with YESCARTA</b></p> <p>The following are signs and symptoms of CRS with YESCARTA</p> <ul style="list-style-type: none"> <li>Capillary leak syndrome</li> <li>Cardiac arrest</li> <li>Cardiac arrhythmias</li> <li>Cardiac failure</li> <li>Chills</li> <li>Fever</li> <li>Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS)</li> <li>Hypotension</li> <li>Hypoxia</li> <li>Renal insufficiency</li> <li>Tachycardia</li> </ul> |

|  |  | <b>Slide Number (new)</b> | <b>Proposed Content (new)</b>   |
|--|--|---------------------------|---|
|  |  | 19                        | <p><b>Patient Assessment of CRS Associated with TECARTUS</b></p> <p>The following are signs and symptoms of CRS with TECARTUS</p> <ul style="list-style-type: none"> <li>Alanine aminotransferase increase</li> <li>Aspartate aminotransferase increased</li> <li>Acute kidney injury</li> <li>Chills</li> <li>Diarrhea</li> <li>Fatigue</li> <li>Fever</li> <li>Headache</li> <li>Hypotension</li> <li>Hypoxia</li> <li>Nausea</li> <li>Tachycardia</li> </ul> |

|     |   | <b>Slide Number (new)</b> | <b>Proposed Content (new)</b>   |
|-----|---|---------------------------|---|
|     |   | 20                        | <p><b>Guidance on Managing CRS for YESCARTA</b></p> <ul style="list-style-type: none"> <li>• Identify CRS based on clinical presentation</li> <li>• Evaluate for and treat other causes of fever, hypoxia, and hypotension</li> <li>• If CRS is suspected, manage according to the recommendations on slide 21</li> <li>• Tocilizumab, an interleukin-6 receptor antagonist, is recommended for the management of Grade 2 or higher CRS associated with YESCARTA</li> <li>• Patients who experience Grade 2 or higher CRS (eg, hypotension, not responsive to fluids, or hypoxia requiring supplemental oxygenation) should be monitored with continuous cardiac telemetry and pulse oximetry</li> <li>• For patients experiencing severe CRS, consider performing an echocardiogram to assess cardiac function</li> <li>• For severe or life-threatening CRS, consider intensive care supportive therapy</li> <li>• Monitor patients at least daily for 7 days at the certified hospitals and their associated clinics following infusion for signs and symptoms of CRS</li> <li>• Monitor patients for signs or symptoms of CRS for 4 weeks after infusion</li> </ul> |
| New | New Slide for Guidance on Managing CRS - YESCARTA | 21                        | <p><b>Guidance on Management of CRS for YESCARTA</b></p> <p>Grading and Management of YESCARTA-Related CRS</p> <p>[Guidance and Management Table per the YESCARTA and TECARTUS Adverse Reaction Management Guide]</p>   |

|  |  | <b>Slide Number (new)</b> | <b>Proposed Content (new)</b>   |
|--|--|---------------------------|---|
|  | New slide for Guidance on Management of CRS - TECARTUS | 22                        | <p><b>Guidance on Managing CRS for TECARTUS</b></p> <ul style="list-style-type: none"> <li>• Identify CRS based on clinical presentation</li> <li>• Evaluate for and treat other causes of fever, hypoxia, and hypotension</li> <li>• If CRS is suspected, manage according to the recommendations on slide 23</li> <li>• Tocilizumab, an interleukin-6 receptor antagonist, is recommended for the management of Grade 1 or higher CRS associated with TECARTUS</li> <li>• Patients who experience Grade 2 or higher CRS (eg, hypotension, not responsive to fluids, or hypoxia requiring supplemental oxygenation) should be monitored with continuous cardiac telemetry and pulse oximetry</li> <li>• For patients experiencing severe CRS, consider performing an echocardiogram to assess cardiac function</li> <li>• For severe or life-threatening CRS, consider intensive care supportive therapy</li> <li>• Monitor patients at least daily for 7 days at the certified hospitals and their associated clinics following infusion for signs and symptoms of CRS</li> <li>• Monitor patients for signs or symptoms of CRS for 4 weeks after infusion</li> </ul> |
|  |  | 23                        | <p><b>Guidance on Management of CRS for TECARTUS</b></p> <p>Grading and Management of TECARTUS-Related CRS</p> <p>[Guidance and Management Table per the YESCARTA and TECARTUS Adverse Reaction Management Guide]</p>   |

|  |  | <b>Slide Number (new)</b> | <b>Proposed Content (new)</b>  |
|--|--|---------------------------|--|
|  |  | 24                        | <b>Management of Neurologic Toxicities</b>   |
|  |  | 25                        | <p><b>Neurologic Toxicities - YESCARTA</b></p> <ul style="list-style-type: none"> <li>• Neurologic toxicities, that were fatal or life-threatening, occurred following treatment with YESCARTA</li> <li>• Neurologic toxicities occurred in 87% of patients, including Grade 3 or higher neurologic toxicities in 31% of patients</li> <li>• 98% of all neurologic toxicities occurred within the first 8 weeks of YESCARTA infusion</li> <li>• The median time to onset was 4 days (range, 1-43 days) following YESCARTA infusion</li> <li>• The median duration was 17 days</li> <li>• Prolonged encephalopathy lasting up to 173 days was noted</li> <li>• Serious events including leukoencephalopathy and seizures occurred with YESCARTA</li> <li>• Fatal and serious cases of cerebral edema have occurred in patients treated with YESCARTA</li> </ul> |
|  |  | 26                        | <p><b>Neurologic Toxicities - TECARTUS</b></p> <ul style="list-style-type: none"> <li>• Neurologic events, including those that were life-threatening, occurred following treatment with TECARTUS</li> <li>• Neurologic events occurred in 81% of patients, 37% of whom experienced Grade 3 or higher (severe or life threatening) adverse reactions</li> <li>• 85% of all treated patients experienced the first CRS or neurological event within the first 7 days after TECARTUS infusion</li> <li>• The median time to onset was 6 days (range, 1-32 days) following TECARTUS infusion</li> <li>• The median duration was 21 days (range, 2-454 days)</li> <li>• Serious events including encephalopathy, aphasia, and seizures occurred with TECARTUS</li> </ul>   |
|  |  | 27                        | <p><b>Patient Assessment of Neurologic Toxicities Associated With YESCARTA</b></p> <p>The following are common signs and symptoms of neurologic toxicities</p>   |

|  |  | <b>Slide Number (new)</b> | <b>Proposed Content (new)</b>  |
|--|--|---------------------------|--|
|  |  |                           | Anxiety<br>Aphasia<br>Delirium<br>Dizziness<br>Encephalopathy<br>Headache<br>Insomnia<br>Tremor  |
|  |  | 28                        | <b>Patient Assessment of Neurologic Toxicities Associated With TECARTUS</b><br>The following are common signs and symptoms of neurologic toxicities<br><br>Aphasia<br>Delirium<br>Encephalopathy<br>Headache<br>Tremor   |
|  |  | 29                        | <b>Guidance on Managing Neurologic Toxicities for YESCARTA and TECARTUS</b> <ul style="list-style-type: none"> <li>• Monitor patients for signs and symptoms of neurologic toxicities</li> <li>• Rule out other causes of neurologic symptoms</li> <li>• Patients who experience Grade 2 or higher neurologic toxicities should be monitored with continuous cardiac telemetry and pulse oximetry</li> <li>• Provide intensive care supportive therapy for severe or life-threatening neurologic toxicities</li> <li>• Consider non-sedating, antiseizure medicines (eg, levetiracetam) for seizure prophylaxis for any Grade 2 or higher neurologic toxicities</li> <li>• Monitor patients at least daily for 7 days at the certified hospitals and their associated clinics following infusion for signs and symptoms of neurologic toxicities</li> <li>• Monitor patients for signs or symptoms of neurologic toxicities for 4 weeks after infusion and treat promptly</li> </ul> |
|  |  | 30                        | <b>Guidance on Managing Neurologic Toxicities for YESCARTA</b>   |

|     |  | <b>Slide Number (new)</b> | <b>Proposed Content (new)</b>  |
|-----|--|---------------------------|--|
|     |  |                           | Grading and Management of YESCARTA-Related Neurologic Toxicities<br>[Grading and Management Table – per the YESCARTA and TECARTUS Adverse Reaction Management Guide for Grade 1 and Grade 2]   |
|     |  | 31                        | <b>Guidance on Managing Neurologic Toxicities for YESCARTA</b><br>Grading and Management of YESCARTA-Related Neurologic Toxicities (continued)<br>[Grading and Management Table – per the YESCARTA and TECARTUS Adverse Reaction Management Guide for Grade 3 and Grade 4] |
| New | New slide for Guidance on Management of Neurologic Toxicities - TECARTUS | 32                        | <b>Guidance on Managing Neurologic Toxicities for TECARTUS</b><br>Grading and Management of TECARTUS-Related Neurologic Toxicities<br>[Grading and Management Table – per the YESCARTA and TECARTUS Adverse Reaction Management Guide for Grade 1 and Grade 2]             |
| New | New Slide for Guidance on Management of Neurologic Toxicities - TECARTUS | 33                        | <b>Guidance on Managing Neurologic Toxicities for TECARTUS</b><br>Grading and Management of TECARTUS-Related Neurologic Toxicities (continued)<br>[Grading and Management Table – per the YESCARTA and TECARTUS Adverse Reaction Management Guide for Grade 3 and Grade 4] |
| New | New Slide for Adverse Event Reporting                                    | 34                        | <b>Adverse Event Reporting</b>   |

|  |  | <b>Slide Number (new)</b> | <b>Proposed Content (new)</b>  |
|--|--|---------------------------|--|
|  |  | 35                        | <p><b>Adverse Event Reporting</b></p> <p>Reporting suspected adverse events after administration of therapy is important. It allows continued monitoring of the risk/benefit balance of therapy.</p> <p>Hospitals and its associated clinics must report any serious adverse event* suggestive of CRS or neurologic toxicities to Kite at <b>1-844-454-KITE</b> (5483) or <a href="mailto:medinfo@kitepharma.com">medinfo@kitepharma.com</a> or FDA at <b>1-800-FDA-1088</b> or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a>. Healthcare providers are also encouraged to report any suspected serious adverse events* associated with YESCARTA or TECARTUS as outlined above.</p> <p>* Serious adverse events are defined as any adverse experience occurring at any dose that results in any of the following outcomes: death, a life-threatening adverse experience, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect</p> |
|  |  | 36                        | <p><b>Patient Counseling</b></p>   |
|  |  | 37                        | <p><b>Patient Counseling</b></p> <ul style="list-style-type: none"> <li>• Talk to the patient about the risk of CRS and neurologic toxicities. Tell them to contact their healthcare provider and/or seek immediate care if experiencing the signs and symptoms associated with CRS and neurologic toxicities: <ul style="list-style-type: none"> <li>- Fever (100.4F/38C or higher)</li> <li>- Difficulty breathing</li> <li>- Chills or shaking chills</li> <li>- Confusion</li> <li>- Dizziness or lightheadedness</li> <li>- Severe nausea, vomiting, or diarrhea</li> <li>- Fast or irregular heartbeat</li> <li>- Severe fatigue or weakness</li> </ul> </li> <li>• Provide the YESCARTA and TECARTUS REMS Patient Wallet Card to the patient or the patient’s caregiver. Tell the patient to carry the Patient Wallet Card at all times and to share the Patient Wallet Card with</li> </ul>  |

|  |  | <b>Slide Number (new)</b> | <b>Proposed Content (new)</b>   |
|--|--|---------------------------|---|
|  |  |                           | <p>any healthcare provider involved in the patient's treatment.</p> <ul style="list-style-type: none"> <li>• Advise patients to refrain from driving or operating heavy or potentially dangerous machinery until at least 8 weeks after YESCARTA or TECARTUS infusion</li> <li>• Instruct patient to remain within close proximity (within 2 hours) of the certified administering hospital and its associated clinics for at least 4 weeks following YESCARTA or TECARTUS infusion.</li> </ul>   |
|  |  | 38                        | <p><b>YESCARTA and TECARTUS REMS Program Resources</b></p>  |
|  |  | 39                        | <p><b>YESCARTA and TECARTUS REMS Program Kit</b></p> <p>Includes:</p> <ul style="list-style-type: none"> <li>• YESCARTA full Prescribing Information and Medication Guide</li> <li>• TECARTUS full Prescribing Information and Medication Guide</li> <li>• YESCARTA and TECARTUS REMS Program Training</li> <li>• YESCARTA and TECARTUS REMS Program Knowledge Assessment</li> <li>• YESCARTA and TECARTUS REMS Program Hospital Enrollment Form</li> <li>• YESCARTA and TECARTUS Adverse Reaction Management Guide</li> <li>• YESCARTA and TECARTUS Patient Wallet Card</li> </ul> |
|  |  | 40                        | <p><b>Additional YESCARTA and TECARTUS REMS Program Information and Resources</b></p> <p>To enroll in the YESCARTA and TECARTUS REMS Program or obtain information regarding enrollment in the program, call 1-844-454-KITE or visit the YESCARTA and TECARTUS REMS Program website at <a href="http://www.YescartaTecartusREMS.com">www.YescartaTecartusREMS.com</a>. The REMS Program website contains the most current version of REMS-related materials.</p> <p>YESCARTA, the YESCARTA Logo, TECARTUS, the TECARTUS Logo, KITE, and the KITE Logo are</p>                       |

|  |  | <b>Slide Number (new)</b> | <b>Proposed Content (new)</b>  |
|--|--|---------------------------|--|
|  |  |                           | trademarks of Kite Pharma, Inc. Gilead is a trademark of Gilead Sciences Inc. ©XXXX Kite Pharma, Inc. All rights reserved. REMS-CTF-0002 MM/YYYY |

REMS-CTF-0002 MM/YYYY